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Interferon-alpha (IFN-a) and interleukin-2 (IL-2) are
cytokines with a variety of immune effects that suggest they
might be useful anticancer agents. Indeed, antitumor res-
ponses to IFN-a or IL-2 have been documented in various
types of experimental and human malignancies, especially
renal-cell carcinoma and malignant melanoma. Published
clinical trials of IFN-alpha and IL-2 in these cancers have
reported response rates in the order of 20% (for a review see
Foon, 1989).
IL-2 therapy is generally administered by i.v. bolus or
continuous infusion at doses of 18 million IU m2 day or
higher. Because of the severity of adverse reactions, these
high-dose i.v. regimens require continous monitoring or even
the admission of patients to intensive-care units (Rosenberg
et al., 1988a; Lee R.E. et al., 1989). Some preclinical data
have documented that the combination of IFN-a and IL-2
produces a better antitumour activity with respect to the
single agent (Cameron et al., 1988; ligo et al., 1988;
Rosenberg et al., 1988b). The mechanism of this synergism is
unknown. One hypothesis is that IFN-a up-regulates the
expression of MHC class I and class II antigens (Faltynek &
Oppenheim, 1988; Goldstein et al., 1989) and that the res-
ponse to IL-2 treatment appears to be strictly related to the
expression of these antigens (Atzpodien et al., 1990a). Based
on these data some investigators have conducted clinical
trials using reduced doses of IL-2 in combination with IFN
(Rosenberg et al., 1989). Recent studies (Lee K.H. et al.,
1989; Atzpodien et al., 1990b; Pichert et al., 1991) have
confirmed that cytokine combination regimens with IL-2
doses in the range of 3 to 9 million IU m2 day and IFN-a are
associated with manageable toxicity and are at least as
effective as more toxic high-dose IL-2 regimens.
Here we describe a regimen consisting of weekly sequential
administration of i.m. IFN-a and varying IL-2 doses. Our
primary aim was to verify if IL-2 doses lower than those used
so far are still able to induce immunologic effects.
Twelve patients with histologically confirmed cancer refrac-
tory to standard therapy or for which no effective standard
therapy is available were included in the study (Table I). All
patients had clinically measurable disease, no chemo/
hormonal/radio or immunotherapy within 4 weeks prior to
study entry, no evidence of brain metastasis. The protocol
was approved by the 'Human Research Ethics Committee' of
the University 'G. D'Annunzio' Medical School, Chieti.
Recombinant IFN-alpha-2b (Schering-Plough, USA) was
given i.m. at the fixed dose of 3 x 106U/m2/day for five
consecutive days during the first week. After a 2-day rest,
groups of patients were treated with escalating doses of
recombinant IL-2 s.c. (EuroCetus, Amsterdam) (240,000 IU
m2 day to 2,400,000 IU m2 day) for 5 consecutive days during
the second week. This schedule was repeated three times for
a total of 6 weeks. All treatments were performed in an
outpatient setting. Four patient groups (two to four patients)
were set up for each IL-2 dose. All patients received
indomethacin and ranitidine throughout the course of treat-
ment. Patients were evaluated for toxicity according to the
WHO criteria (WHO Geneva, 1979).
Percentages of lymphocyte subsets and in vitro lytic assays
were performed on patients' peripheral blood mononuclear
(PBM) cells isolated from heparinised venous blood samples
after centrifugation through Ficoll. Surface marker analysis
was performed using a Profile II Flow Cytometer (Coulter
Electronics) after conjugation with fluorescein-labelled mono-
clonal antibodies CD2 (mature T-cells), CD4 (helper/induc-
er), CD8 (cytotoxic/suppressor), CD25 (IL-2 receptor), CD14
and CD16 (natural killer cells), and HLA-DR. Target cells
for the assays of lymphocyte natural killer cytotoxic activity
(NK) were the human erythroleukemia cell line K562 (a
natural killer-sensitive cell line) and for the lymphokine
activated killer cell activity (LAK) the Burkitt's lymphoma
cell line Daudi (a natural killer-resistant cell line). Target cells
were labelled by adding 100 iLCi "Cr/107 cells and incubating
for 1 h at 37'C. The cells were washed twice and then
incubated for 30 min at 37'C in RPMI culture medium.
Following this incubation, the labelled cells were washed two
more times and 2 x 105 cells in 50 il of medium were added
to the wells of a round bottom tissue culture microplate.
Effector cells were added to make final effector:target cell
ratios of 40:1, 10:1, 2.5:1. Plates were briefly centrifuged
and then incubated at 37'C for 4 h. SuRernatants were
removed using a Skatron harvesting apparatus (Skatron,
Lier, Norway) and the radioactivity was determined with a
gamma counter. A solution of 0.1 N HCI and culture
medium were used instead of effector cells to determine
maximal (MR) and spontaneous (SR) release, respectively, of
radioactivity from target cells. The percentage of specific
tumour cell lysis was calculated using the formula:
c.p.m. sample - c.p.m. SR
% Specific lysis =cm M ...S
c.p.m. MR c.p.m. SR
All assays were done in quadruplicate.
Statistical significance was assessed with two-group t test
and the paired two sided t-test.
An increase of NK and LAK activities over pretreatment
levels was seen after the first 2 weeks of treatment. This
increase did not reach statistical significance (Figure 1). After
the 6-week cycle, the mean increase was about 50% for NK
activity (P<0.005) and 345% for LAK activity (P<0.01),
respectively. The behaviour of individual patients is illus-
trated in Figure 2. Enhanced NK activity was seen in ten of
12 patients and enhanced LAK activity in 11 of 12 patients,
unrelated to the dose of IL-2 administered. The number of
total lymphocytes and the percentages of lymphocytes subsets
after 6 weeks of treatment did not show variations with
respect to baseline values (not shown).
Toxicity was limited to WHO grade I and II except for one
patient who developed grade III neurological toxicity (som-
nolence lasting >50% of waking hours) regressing within 2
days from the suspension of treatment. More frequent side
effects were fever, chills, malaise and fatigue. The sub-
cutaneous administration of IL-2 resulted in transient
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Table I Patient characteristics
Pts Age Performance Prior Dose if IL-2
No. (yrs) Sex status treatment Diagnosis IUmn2 die
1 25 M 1 CT + IT Cutaneous melanoma 240,000
2 62 M 2 RT + CT Small cell lung carcinoma 240,000
3 65 F 0 IT Ocular melanoma 240,000
4 39 F 0 CT Ocular melanoma 240,000
5 60 M 1 None Ocular melanoma 600,000
6 48 F 1 CT Fallopian tubes carcinoma 600,000
7 61 M 1 None Kidney carcinoma 1,200,000
8 70 M I CT Pancreas carcinoma 1,200,000
9 43 M 1 CT + IT Kidney carcinoma 1,200,000
10 57 M 1 CT Hepatocarcinoma 1,200,000
11 60 F 1 None Kidney carcinoma 2,400,000
12 57 M 0 CT + IT Kidney carcinoma 2,400,000
CT, chemotherapy; IT, immunotherapy; RT, radiotherapy.
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Figure 1 Mean levels of NKI a, and LAK b, activity in all
patient population evaluated before treatment ( ), after 2
weeks ( U-), and at the end (-A-) of a treatment at various
Effector:Target ratios (see 'Materials and methods'). P values vs
baseline by paired t test: *<0.05; **<0.01; ***<0.005; ns, not
significant.
inflammation and local induration at the injection site, which
persisted for up to 2 weeks after treatment. However, none of
the patients judged this side-effect as unacceptable. No
ulceration occurred.
Three patients with renal-cell carcinoma and one with
ocular melanoma showed disease stabilisation for at least 3
months. No objective responses were observed.
Our combination regimen containing low IL-2 doses was
able to induce immunological changes. Significant enhance-
ment of NK and LAK activity was observed in the majority
of the patients. The extent of the immune activation was
about of the same order of magnitude as that observed using
much higher IL-2 doses (Rosenberg, 1986; Sondel, 1988).
This further supports the concept previously expressed by
others (Hank et al., 1988; Rosenthal et al., 1988; Urba et al.,
1990) that long term chronic exposure to low dose IL-2
might be more efficient than short-term stimulation by high-
dose to obtaining significant immunological effects.
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Figure 2 Levels of NK a, and LAK b, activity in individual
patients before (U) and at the end (0) of the 6-week treatment
cycle at a fixed Effector:Target ratio of 40: 1. P values vs baseline
(two-group t-test): * <0.02; ** <0.002; ns, not significant.
The stimulation of immune functions was already evident
at the lowest IL-2 doses. Four patients received more than
one course of therapy. Among these, two patients enrolled at
the beginning of the study receiving 240,000 and 600,000 IU
m2day, respectively, showed maximal stimulation of LAK
activity that persisted during three consecutive 6-week cycles
(not shown). Patient heterogeneity with regard to tumour
burden, tumour type, and previous treatment may explain
why enhanced cellular cytotoxicity was seen in some patients
but not in others independently of the amount of IL-2
administered. One additional cause of heterogeneity could be
the variable production of neutralising antibodies on IL-2
activity in vivo as evidenced in a recent report (Whitehead et
al., 1990). These same reasons could explain our inability to
consistently see alterations in the distribution of lymphocyte
subsets.
In summary, this investigation shows that long-term
sequential weekly IFN-a and low-dose IL-2 possesses
immunological activity in patients with cancer. The regimen
is provided with low toxicity, and prolonged treatment is
possible with little inconvenience to the patient. Since
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patients can be easily trained to give their own s.c. IL-2
injections (Atzpodien et al., 1990b; Stein et al., 1991), our
regimen may be suitable for study as possible adjuvant in the
treatment of IL-2 sensitive malignancies.
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